Form 8-K Black Diamond Therapeuti For: May 21
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
Go back to Form 8-K Black Diamond Therapeuti For: May 21
May 22, 2026 9:38 AM EDT
Raymond James analyst Sean McCutcheon reiterated an Outperform rating and $11.00 price target on Black Diamond Therapeutics (NASDAQ: BDTX).
The analyst comments "Thursday, after market close, ASCO 2026 regular abstracts were released, and in conjunction Black Diamond reported the topline result for the longer-term follow-up from their Phase 2... More
May 22, 2026 9:37 AM EDT
Stifel analyst Laura Prendergast reiterated a Buy rating and $8.00 price target on Black Diamond Therapeutics (NASDAQ: BDTX).
The analyst comments "We view the preliminary median PFS of 15.2 months as highly encouraging and perhaps practice changing - the DoR had not yet been reached. 44% of patients are progression free/still on drug with median follow up ~9.8 months, suggesting PFS could increase with longer follow up. What stands out to us the most is: The breadth of mutations seen in patients who are progression free for 1 year (10 unique mutations across 8 patients). The lack of any CNS... More
